Carteolol

DEA Class;  Rx

Common Brand Names; Ocupress (DSC)

  • Antiglaucoma, Beta-Blockers

Long-acting, nonselective, beta-blocker; oral product used for HTN; ophthalmic product indicated for open-angle glaucoma or ocular hypertension; low lipid solubility; moderate intrinsic sympathomimetic activity (ISA).

Indicated for the treatment of chronic open-angle glaucoma and ocular hypertension either alone or in combination with other intraocular pressure lowering agents.

Asthma, uncompensated CHF, any beta-blocker side effects, hypersensitivity, severe COPD, 2°/3° AV block, cardiogenic shock

  • Burning sensation in eye (25%)
  • Conjunctival hyperemia (25%)
  • Excessive tear production (25%)
  • Eye irritation (25%)
  • Blurred and cloudy vision
  • Photophobia
  • Decreased night vision
  • Ptosis
  • Ocular signs including blepharoconjunctivitis, abnormal corneal staining, and corneal sensitivity occurred occasionally
  • Systemic side effects may be similar to systemic beta-blockers (bradycardia, aggravation of CHF, asthma, caution in diabetes as may mask signs of hypolgycemia, nightmares, impotence, tiredness, etc)
  • Reduction of systemic side effects by putting finger in corner of eye (occluding punctum) or by gentle eyelid closure (without opening & closing lid) for 3 min

Pregnancy Category: C

Lactation: excretion in milk unknown; use with caution

Adults

2 drops/day 1% carteolol ophthalmic solution in the affected eye(s).

Geriatric

2 drops/day 1% carteolol ophthalmic solution in the affected eye(s).

Adolescents

Safety and efficacy have not been established.

Children

Safety and efficacy have not been established.

Carteolol hydrochloride

ophthalmic solution

  • 1%

About the Author

You may also like these

0